The Gluten-Free Revolution: New IL-2 Blood Test Diagnoses Celiac Disease Without Gluten Challenge

A diagram showing how the IL-2 blood test works: T-cells from a gluten-free patient’s blood are exposed to gluten in vitro, triggering an IL-2 immune response if the person has celiac disease/ Pexels

A novel blood test measuring interleukin-2 release from gluten-specific T cells can diagnose celiac disease with up to 97% accuracy—no gluten ingestion required.

Why This Matters

About 1% of Western populations have celiac disease, yet over half remain undiagnosed due to the burdensome requirement of reintroducing gluten before testing. Symptoms like bloating, diarrhea, and abdominal pain deter many from seeking diagnosis, delaying treatment and increasing long-term risks.

Breakthrough Assay: IL-2 as a Biomarker

Led by Professor Jason Tye-Din at Australia’s Walter and Eliza Hall Institute (WEHI), researchers collaborated with Novoviah Pharmaceuticals to develop a whole-blood assay that exposes patient samples to gluten in vitro. The test measures the spike in interleukin-2 (IL-2), an immune signaling molecule released by gluten-reactive CD4⁺ T cells.

Clinical Trial Design & Results

Participants (n=181):
- 75 on a strict gluten-free diet for ≥1 year (known celiac)
- 13 with active, untreated celiac disease
- 32 with non-celiac gluten sensitivity
- 61 healthy controls
Sensitivity: 90%
Specificity: 97%

These metrics demonstrate the test’s ability to correctly identify celiac patients and rule out non-celiac subjects without requiring a gluten challenge.

Expert Insights

Associate Professor Olivia Muscatelli (WEHI), herself diagnosed at 18, emphasizes how this test “removes one of the biggest barriers in current diagnostic practices.”

Professor Peter Gibson (Monash University) calls the simplicity and accuracy of the IL-2 assay “very impressive” and suitable for broad clinical adoption.

Associate Professor Vincent Ho (Western Sydney University) cautions that further validation across labs and cost-effectiveness analyses are needed before replacing the tTG antibody test, which still requires gluten intake.

Next Steps & Availability

Novoviah Pharmaceuticals aims to introduce the IL-2 assay into clinical settings within two years. Future studies will test pediatric and immunosuppressed populations, as well as head-to-head comparisons with current serologic benchmarks.